Insecticides India Ltd
Insecticides India is into manufacturing of agrochemicals (technicals and formulations) and biological and household products. They cater to Indian market where they directly sell to the end consumer and also sell technicals and formulations to the companies who are in the business of formulation. They also export to 30 countries with more than 100 customers through registrations. IIL has more than 75 registrations so far.[1]
- Market Cap ₹ 1,711 Cr.
- Current Price ₹ 578
- High / Low ₹ 1,085 / 460
- Stock P/E 12.8
- Book Value ₹ 377
- Dividend Yield 0.52 %
- ROCE 13.0 %
- ROE 10.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 10.5% over past five years.
- Company has a low return on equity of 10.1% over last 3 years.
- Dividend payout has been low at 9.43% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Part of BSE SmallCap BSE Allcap BSE Commodities
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
566 | 801 | 892 | 906 | 994 | 1,073 | 1,194 | 1,363 | 1,420 | 1,504 | 1,801 | 1,966 | 1,916 | |
498 | 719 | 781 | 815 | 880 | 925 | 1,006 | 1,207 | 1,268 | 1,333 | 1,679 | 1,803 | 1,716 | |
Operating Profit | 68 | 82 | 111 | 91 | 114 | 148 | 188 | 156 | 153 | 171 | 122 | 163 | 200 |
OPM % | 12% | 10% | 12% | 10% | 11% | 14% | 16% | 11% | 11% | 11% | 7% | 8% | 10% |
1 | 0 | 0 | 0 | 4 | 3 | 0 | 2 | -2 | 3 | 1 | 10 | 9 | |
Interest | 17 | 27 | 33 | 26 | 20 | 16 | 15 | 24 | 7 | 7 | 13 | 11 | 7 |
Depreciation | 6 | 7 | 14 | 16 | 16 | 17 | 20 | 24 | 25 | 26 | 26 | 29 | 30 |
Profit before tax | 46 | 49 | 64 | 50 | 82 | 118 | 153 | 110 | 119 | 141 | 84 | 133 | 172 |
Tax % | 24% | 18% | 15% | 21% | 28% | 29% | 20% | 22% | 22% | 24% | 25% | 23% | |
35 | 40 | 55 | 39 | 59 | 84 | 122 | 86 | 93 | 107 | 63 | 103 | 134 | |
EPS in Rs | 12.39 | 14.01 | 19.24 | 12.67 | 19.16 | 27.09 | 39.49 | 27.75 | 30.14 | 36.16 | 21.28 | 34.67 | 45.21 |
Dividend Payout % | 11% | 10% | 0% | 11% | 7% | 5% | 3% | 10% | 4% | 6% | 14% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 11% |
3 Years: | 11% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -4% |
3 Years: | 0% |
TTM: | 104% |
Stock Price CAGR | |
---|---|
10 Years: | 6% |
5 Years: | 13% |
3 Years: | 14% |
1 Year: | 7% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 21 | 21 | 21 | 21 | 21 | 21 | 20 | 30 | 30 | 30 |
Reserves | 200 | 234 | 279 | 388 | 444 | 527 | 641 | 710 | 798 | 847 | 886 | 982 | 1,087 |
211 | 258 | 322 | 206 | 237 | 114 | 305 | 191 | 100 | 54 | 163 | 87 | 66 | |
209 | 287 | 308 | 322 | 277 | 338 | 388 | 372 | 505 | 473 | 615 | 611 | 627 | |
Total Liabilities | 632 | 791 | 921 | 936 | 978 | 1,000 | 1,355 | 1,293 | 1,424 | 1,394 | 1,694 | 1,710 | 1,809 |
140 | 170 | 205 | 194 | 185 | 232 | 240 | 239 | 239 | 253 | 262 | 283 | 293 | |
CWIP | 45 | 54 | 38 | 51 | 58 | 17 | 19 | 39 | 59 | 91 | 123 | 141 | 136 |
Investments | 0 | 11 | 11 | 11 | 11 | 16 | 12 | 10 | 12 | 13 | 15 | 19 | 21 |
447 | 556 | 667 | 680 | 725 | 735 | 1,084 | 1,004 | 1,115 | 1,037 | 1,293 | 1,267 | 1,359 | |
Total Assets | 632 | 791 | 921 | 936 | 978 | 1,000 | 1,355 | 1,293 | 1,424 | 1,394 | 1,694 | 1,710 | 1,809 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | 38 | -6 | 85 | 4 | 182 | -133 | 242 | 155 | 135 | -11 | 185 | |
-46 | -57 | -33 | -19 | -14 | -26 | -49 | -24 | -113 | 9 | -87 | -44 | |
35 | 23 | 36 | -63 | 9 | -143 | 172 | -159 | -104 | -115 | 80 | -98 | |
Net Cash Flow | -13 | 4 | -2 | 3 | -0 | 13 | -11 | 59 | -61 | 30 | -18 | 43 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 75 | 58 | 68 | 84 | 78 | 80 | 75 | 86 | 65 | 70 | 60 | 55 |
Inventory Days | 221 | 189 | 220 | 190 | 232 | 214 | 355 | 202 | 248 | 228 | 247 | 220 |
Days Payable | 128 | 124 | 118 | 114 | 108 | 128 | 141 | 96 | 136 | 117 | 128 | 114 |
Cash Conversion Cycle | 168 | 124 | 170 | 159 | 201 | 166 | 289 | 192 | 177 | 181 | 178 | 161 |
Working Capital Days | 147 | 115 | 138 | 137 | 155 | 126 | 206 | 147 | 132 | 123 | 124 | 109 |
ROCE % | 16% | 16% | 17% | 12% | 16% | 20% | 21% | 14% | 15% | 16% | 10% | 13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
13 Feb - Transcript of Q3 FY25 Earnings Conference Call.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Feb - Newspaper advertisement of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2024
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10 Feb - Audio recording of Q3 earnings conference call available.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10 Feb - Q3 & 9M FY2025 financial results announcement.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
10 Feb - Enclosing Earning Presentation for Q3 & 9M of FY 2025 Results
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Dec 2022TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Dec 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Sep 2018TranscriptNotesPPT
Product Offerings
The company is one of India’s leading crop protection and Nutrition companies, with a portfolio of 20+ technical products and 125 formulation products, including Insecticides, Herbicides, Fungicides, and Biological and PGR products, under brands like Tractor, Green Label, Pulsor, Hakama, and others. Its premium portfolio includes 11 Focused Maharatna products and 33 Maharatna under brands like Hercules, Lethal, Hachiman, Shinwa, etc. [1] [2] [3] [4]